Speaker's Highlight

• Don Sin University of British Columbia, St. Paul Hospital (Canada)
  Kenneth R. Chapman Toronto General Hospital Research Institute (Canada)
• Parameswaran Nair McMaster University (Canada)
  Carolyn Calfee UCSF (U.S.A.)
• Gregory P. Downey University of Colorado School of Medicine (U.S.A.)
  David A. Schwartz University of Colorado School of Medicine (U.S.A.)
• Neil Schluger Tuberculosis Control Branch, California Department of Public Health (U.S.A.)
  Nick Kim Critical Care & Sleep Medicine, University of California San Diego (U.S.A.)
• Nicola Hananiah Baylor College of Medicine (U.S.A.)
  Jae-Joon Yim Seoul National University College of Medicine (Republic of Korea)
• Koichiro Asano Tokai University School of Medicine (Japan)
  Diahn-Warng Perng Taipei Veterans General Hospital (Taiwan)
• Konstantinos Kostikas University of Ioannina (Greece)
  Karin Klooster University Medical Center Groningen (Kingdom of the Netherlands)

• How genes shape susceptibility to acute respiratory distress syndrome

  Acute respiratory distress syndrome remains one of the most life-threatening pulmonary conditions encountered in intensive care settings worldwide. While environmental triggers such as sepsis, pneumonia, or trauma are well-recognised catalysts, emerging evidence points to a deeper biological narrative in which hereditary factors shape individual vulnerability. Researchers across Australia and abroad are now mapping how subtle variations within immune and structural genes influence why some patients deteriorate rapidly while others recover with comparatively mild symptoms.

  The concept of genetic predisposition reframes how clinicians approach risk stratification. Rather than viewing ARDS as a uniform response to acute injury, the contemporary view recognises a mosaic of inherited susceptibility patterns interacting with environmental insults. This shift carries significant weight for Australian hospitals, where diverse patient populations, including First Nations communities with distinct respiratory disease profiles, stand at the intersection of genetic research and clinical care.

  Understanding the genetic basis of ARDS susceptibility

  The earliest clues about inherited susceptibility came from observational studies noting that patients with similar insults developed vastly different clinical trajectories. Twin studies and familial aggregation analyses subsequently suggested that heritable factors could account for a substantial proportion of this variability. Modern genome-wide association studies have confirmed that vulnerability to acute respiratory distress syndrome involves multiple loci rather than a single deterministic gene.

  These discoveries have been particularly relevant at institutions such as the Garvan Institute of Medical Research in Sydney, where teams have contributed to international consortia examining immune-related polymorphisms. Australian researchers have helped identify single nucleotide variants in genes regulating innate immune recognition, surfactant production, and vascular permeability, all of which modulate the threshold at which the lungs shift from controlled inflammation to catastrophic injury.

  Inflammatory pathway genes and respiratory outcomes

  Inflammatory signalling sits at the heart of ARDS pathophysiology, and genetic variation within cytokine and chemokine genes shapes the magnitude of each patient's response. Polymorphisms in interleukin-6, tumour necrosis factor-alpha, and various toll-like receptor genes have all been linked to differential outcomes across cohorts. The presence of hyper-responsive alleles can amplify the cytokine cascade, tipping the balance toward diffuse alveolar damage.

  For clinicians working in Australian intensive care units, this knowledge has tangible implications. The Australian and New Zealand Intensive Care Society has supported registry-based research examining how genetic markers correlate with mechanical ventilation duration and mortality. Patterns emerging from these datasets suggest that local populations carry allele frequencies that differ subtly from those reported in European and North American studies, reinforcing the need for region-specific reference data.

  Endothelial and epithelial genetic factors

  Beyond inflammation, the structural integrity of the alveolar-capillary barrier depends on tightly regulated genes governing endothelial and epithelial function. Variants in genes such as ACE, angiopoietin-2, and aquaporin-5 influence vascular tone, leakiness, and fluid clearance. When these protective mechanisms falter, protein-rich oedema floods the alveolar spaces, undermining gas exchange and driving hypoxaemia.

  Australian clinicians have observed that patients with pre-existing pulmonary conditions sometimes progress toward ARDS more readily when exposed to insults such as severe influenza or aspiration events. Research collaborations involving the Royal Melbourne Hospital and the Florey Institute have explored how background genetic vulnerability amplifies environmental risk. These findings sit alongside broader respiratory work, including studies on post-tuberculosis lung disease, where genetic and structural factors similarly determine long-term outcomes.

  Population studies and Australian research contributions

  Large-scale population studies have been essential in distinguishing genuine genetic signals from statistical noise. Biobank-linked projects and intensive care registries now permit researchers to trace genetic markers against documented clinical courses. In Australia, partnerships between universities, hospitals, and organisations such as the Murdoch Children's Research Institute have accelerated this field, particularly through studies involving paediatric ARDS cohorts.

  Australian contributions also extend to studying how environmental exposures specific to the continent influence genetic expression. The 2019 and 2020 bushfire season generated unprecedented air quality crises across Sydney, Melbourne, and Canberra, exposing millions to particulate matter and prompting researchers to investigate gene-environment interactions. Subsequent studies have begun to reveal how bushfire-related particulates may unmask latent genetic susceptibilities, producing ARDS-like phenotypes in previously resilient individuals. Work exploring the heightened respiratory disease burden among Aboriginal and Torres Strait Islander populations underscores how ancestral genetic diversity intersects with social determinants of health.

  Clinical implications for precision respiratory medicine

  Translating genetic discoveries into bedside decisions remains the field's central challenge. Pharmacogenomic insights are beginning to inform drug selection, with certain anti-inflammatory agents appearing more effective in patients carrying particular cytokine gene variants. Risk prediction models that integrate genetic scores alongside clinical variables are being piloted in research settings, offering a more nuanced prognosis than traditional severity indices alone.

  Practical considerations for Australian clinicians include ensuring informed consent processes address genetic testing transparently, especially when working with culturally diverse communities. Engaging patients from Indigenous backgrounds requires culturally safe communication, recognising the historical sensitivities surrounding biospecimen research. Hospitals also need to align with Medicare reimbursement frameworks and local laboratory accreditation standards when introducing genetic panels into ARDS workups.

  Recommendations for integrating genetic awareness into respiratory practice

  • Establish multidisciplinary teams combining intensivists, geneticists, and bioinformaticians.
  • Participate in national and international ARDS registries to strengthen population-level datasets.
  • Adopt culturally safe consent protocols that respect the values of Aboriginal and Torres Strait Islander patients.
  • Incorporate gene-environment interaction models into research on local exposures such as bushfire smoke and dust storms.
  • Stay engaged with evolving pharmacogenomic evidence to refine immunomodulatory treatment choices.

  The lasting message for clinicians, researchers, and patients is that acute respiratory distress syndrome is no longer a uniform clinical event but a deeply individual response shaped by inheritance, environment, and the broader social context of care. Australian medicine stands at an exciting frontier where genetic understanding promises earlier recognition, more accurate prognosis, and ultimately more effective treatment for those at greatest risk.

  Richard Russell Nuffield Department of Clinical Medicine, University of Oxford (United Kingdom)
• Mona Bafadhel King’s College London (United Kingdom)
  David Jackson Guy’s and St Thomas’ Hospital, King’s College London (United Kingdom)
• James Chalmers University of Dundee (United Kingdom)
  David Price University of Aberdeen (United Kingdom)